302 related articles for article (PubMed ID: 11522017)
21. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
[TBL] [Abstract][Full Text] [Related]
22. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
Ye S; Green FR; Scarabin PY; Nicaud V; Bara L; Dawson SJ; Humphries SE; Evans A; Luc G; Cambou JP
Thromb Haemost; 1995 Sep; 74(3):837-41. PubMed ID: 8571307
[TBL] [Abstract][Full Text] [Related]
23. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
[TBL] [Abstract][Full Text] [Related]
24. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
Testa R; Bonfigli AR; Sirolla C; Marra M; Boemi M; Mari D; Sacchi E; Dolci A; Catalano A; Procopio A; Ceriello A
Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism.
Brogren H; Wallmark K; Jern S; Karlsson L
Thromb Res; 2008; 121(6):793-7. PubMed ID: 17884148
[TBL] [Abstract][Full Text] [Related]
26. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
Roncal C; Orbe J; Rodriguez JA; Belzunce M; Beloqui O; Diez J; Páramo JA
Cardiovasc Res; 2004 Jul; 63(1):176-85. PubMed ID: 15194475
[TBL] [Abstract][Full Text] [Related]
27. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
Zöller B; García de Frutos P; Dahlbäck B
Thromb Haemost; 1998 Apr; 79(4):802-7. PubMed ID: 9569196
[TBL] [Abstract][Full Text] [Related]
28. Association of 4G/5G polymorphism in PAI1 promoter with PAI1 level in deep vein thrombosis.
Chen YL; Zhang JX; Wang PX; Cui RZ; Zhao FM; Mao YM; Li JY; Bi YY; Li H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Dec; 22(6):624-7. PubMed ID: 16331557
[TBL] [Abstract][Full Text] [Related]
29. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation.
Ma Z; Paek D; Oh CK
Clin Exp Allergy; 2009 Aug; 39(8):1136-44. PubMed ID: 19438580
[TBL] [Abstract][Full Text] [Related]
31. Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal.
Wiwanitkit V
Arch Gynecol Obstet; 2006 Mar; 273(6):322-4. PubMed ID: 16502012
[TBL] [Abstract][Full Text] [Related]
32. [The influences of genetic and environmental factors on plasma plasminogen activator inhibitor-1 levels in patients with essential hypertension].
Song Y; Xu W; Chen Y; Che L; Wang Q; Zhou X; Wu J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Dec; 16(6):374-6. PubMed ID: 10581347
[TBL] [Abstract][Full Text] [Related]
33. Relationship between plasminogen activator inhibitor-1 antigen, leptin, and fat mass in obese children and adolescents.
Sudi KM; Gallistl S; Weinhandl G; Muntean W; Borkenstein MH
Metabolism; 2000 Jul; 49(7):890-5. PubMed ID: 10910001
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility.
Hizawa N; Maeda Y; Konno S; Fukui Y; Takahashi D; Nishimura M
Clin Exp Allergy; 2006 Jul; 36(7):872-6. PubMed ID: 16839401
[TBL] [Abstract][Full Text] [Related]
35. [The study of PAI-1 promotor region gene polymorphism in cerebrovascular disease].
Zhang C; Li J; Li L; Luo B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Oct; 18(5):383-7. PubMed ID: 11592048
[TBL] [Abstract][Full Text] [Related]
36. Distribution of PAI-1 promoter 4G/5G polymorphism in healthy Chinese and functional characterization using a luciferase reporter vector.
Ding Z; Pan JQ
Ann Hematol; 2005 Mar; 84(3):183-7. PubMed ID: 15309528
[TBL] [Abstract][Full Text] [Related]
37. [Genetic variations in plasminogen activator inhibitor-1 gene and beta fibrinogen gene associated with glomerular microthrombosis in lupus nephritis and the gene dosage effect].
Gong R; Liu Z; Chen Z; Li L
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):1-5. PubMed ID: 11836675
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
Mansfield MW; Stickland MH; Grant PJ
Thromb Haemost; 1995 Oct; 74(4):1032-4. PubMed ID: 8560407
[TBL] [Abstract][Full Text] [Related]
39. Weight loss induced by 6-month lifestyle intervention improves early endothelial activation and fibrinolysis in obese adolescents.
Huang F; del-Río-Navarro BE; de Castro GT; Alcántara ST; Sienra Monge JJ; Ontiveros JA; Olivos EN; Barron MF; Lopéz AR; Villafaña S; Hong E
Child Care Health Dev; 2011 May; 37(3):377-84. PubMed ID: 21198775
[TBL] [Abstract][Full Text] [Related]
40. [The role of 4G/5G polymorphism in the regulation of plasma levels of PAI-1: a model of interaction between genetic and environmental factors].
Burzotta F; Di Castelnuovo A; Amore C; D'Orazio A; Donati MB; Iacoviello L
Cardiologia; 1998 Jan; 43(1):83-8. PubMed ID: 9534297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
